Skip to main content
. 2018 Apr 4;9:621. doi: 10.3389/fimmu.2018.00621

Table 1.

Characteristics of LPD and control RA patients.

Regressive group (n = 22) Persistent group (n = 13) Control group (n = 35) Regressive vs. persistent, P Regressive vs. control, P Persistent vs. control, P
Demographics
Age (years) 67 (58–73) 67 (64–71) 66 (57–72) 0.64 0.98 0.66
Female, n (%) 20/22 (91%) 11/13 (85%) 31/35 (89%) 0.57 0.78 0.71
RA features
RA disease duration (months) 132 (57–227) 132 (115–298) 155 (88–201) 0.62 0.74 0.95
RF positive, n (%) 17/20 (85%) 9/13 (69%) 28/35 (80%) 0.28 0.64 0.43
ACPA positive, n (%) 14/18 (78%) 3/7 (43%) 17/23 (74%) 0.10 0.77 0.13
TJC 1 (0–3) 0 (0–2) 0 (0–1) 0.78 0.74 0.48
SJC 1 (0–3) 1 (0–2) 0 (0–2) 0.44 0.47 0.06
MTX duration (months) 65 (23–99) 98 (72–120) 87 (49–115) 0.08 0.17 0.41
MTX dose (mg/week) 10 (6–12) 8 (6–12) 10 (6–12) 0.82 0.61 0.56
MTX cumulative dose (mg) 2,080 (844–3,849) 3,064 (1,810–3,744) 2,760 (1,408–4,144) 0.29 0.46 0.99
Concomitant DMARDs 12/22 (55%) 6/13 (46%) 14/35 (40%) 0.63 0.28 0.70
Sjögren’s syndrome 2/22 (9%) 4/13 (31%) 3/35 (9%) 0.11 0.95 0.07
LPD features
Pathological phenotype (n, %)

  • cHL

  • DLBCL

  • FL

  • MALT lymphoma

  • NKT cell lymphoma

  • LYG

  • Reactive hyperplasia

  • LPD with atypical cell proliferation

  • 2 (9%)

  • 14 (64%)

  • 0 (0%)

  • 1 (5%)

  • 1 (5%)

  • 2 (9%)

  • 1 (5%)

  • 1 (5%)

  • 6 (46%)

  • 4 (31%)

  • 2 (15%)

  • 0 (0%)

  • 0 (0%)

  • 0 (0%)

  • 0 (0%)

  • 1 (8%)

  • –

  • –

  • –

  • –

  • –

  • –

  • –

  • –

 0.07 – –
EBER positive, n (%) 13/19 (68%) 7/11 (64%) – 0.79 – –
Clinical stage, I/II/III/IV, n (%) 10/4/4/4 (45/18/18/18, %) 3/3/5/2 (23/23/38/15, %) – 0.47 – –
White blood cell count (× 103/μL) 4.7 (3.0–7.0) 6.1 (4.4–8.3) 5.5 (4.4–6.4) 0.14 0.26 0.52
Lymphocyte count (/μL) 508 (286–825) 1,165 (517–2,035) 1,321 (1,045–1,691) <0.01* 0.01* 0.55
LDH (IU/L) 226 (186–314) 257 (189–342) 194 (170–226) 0.82 0.02* 0.02*
CRP (mg/dL) 1.48 (0.26–2.88) 0.9 (0.11–2.20) 0.08 (0.03–0.47) 0.31 <0.01* <0.01*
IgG (mg/dL) 1,218 (1,052–1,451) 1,511 (1,228–1,986) 1,518 (1,195–1,689) 0.05 0.12 0.63
sIL-2R (IU/L) 871 (447–1,436) 1,910 (894–2,600) – 0.15 – –

LPD, lymphoproliferative disorder; RA, rheumatoid arthritis; RF, rheumatoid factor; ACPA, anti-cyclic citrullinated peptides antibody; TJC, tender joint count; SJC, swollen joint count; MTX, methotrexate; DMARD, disease-modifying anti-rheumatic drug; cHL, classical Hodgkin’s lymphoma; DLBCL, diffuse large B cell lymphoma; FL, follicular lymphoma; LYG, lymphomatoid granulomatosis; MALT, mucosa-associated lymphoid tissue; EBER, Epstein–Barr virus-excreted RNA; LDH, lactate dehydrogenase; CRP, C-reactive protein; IgG, immunoglobulin G; sIL-2R, soluble IL-2 receptor.

*P < 0.05.